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EDITORIAL REVIEW
Leukocyte adhesion molecules and kidney diseases
Phagocytic leukocytes, particularly neutrophils and mono-
cytes, are important effectors of injury in many forms of
glomerulonephritis, vasculitis, tubulointerstitial nephntis and
allograft rejection [1—41. Current treatment strategies for these
diseases lack immunologic specificity and are frequently toxic,
reflecting our relatively naive understanding of the pathophys-
iology of renal inflammation. Recent advances in immunopa-
thology research have identified leukocyte adhesion as a pivotal
event in inflammation that may be amenable to therapeutic
intervention. Adhesion is mediated by interaction of cell sur-
face adhesion molecules on leukocytes with cognate ligands on
resident tissue cells. The leukocyte adhesion molecules are
members of larger superfamilies of cell surface receptors that
play critical roles in immunosurveillance, inflammation, hemo-
stasis, wound healing, morphogenesis, maintenance of tissue
architecture, atherogenesis, and tumor metastasis. This contri-
bution (a) reviews the classification, biochemical structures and
cognate ligands of the major leukocyte adhesion molecules
[5—21], (b) discusses the mechanisms by which inflammatory
mediators regulate leukocyte adhesion [5—14, 22—38], (c) sum-
marizes the distribution of leukocyte adhesion molecules in
normal and diseased kidneys [12—14, 39—72], (d) highlights the
dynamic interplay that occurs between leukocytes and resident
tissue cells during cell-cell adhesion [73—80], and (e) reviews
recent studies evaluating the efficacy of monoclonal antibodies
(mAb) against leukocyte adhesion molecules in the treatment of
renal inflammation [81—91]. These exciting advances may ante-
cede the development of potent and specific new agents for the
treatment of inflammatory diseases of the kidney.
Overview of recruitment of phagocytic leukocytes to sites of
inflammation
It is useful to review briefly normal phagocyte physiology
before discussing the role of these cells in the pathogenesis of
"autoimmune" renal disease. Phagocytes play a pivotal role in
the initial defense against bacterial and fungal infections. The
recruitment of circulating phagocytes to sites of infection in-
volves a series of coordinated steps which include directed
locomotion up concentration gradients of chemoattractants
(chemotaxis), adhesion to vascular endothelial cells in the area
of inflammation (margination), penetration of tight junctions,
and migration between endothelial cells (diapedesis) and
through basement membrane and extravascular tissue to the
inflammatory focus. Phagocytes ingest (phagocytosis) and de-
stroy foreign antigens through the actions of a variety of toxic
molecules, including reactive oxygen species and proteolytic
enzymes. This orchestrated response ultimately facilitates the
destruction of antigens within phagocytes with relative preser-
vation of surrounding host tissue.
The dramatic functional abnormalities that characterize acute
glomerulonephntis underscore the devastating consequences of
inappropriate activation of this cascade in autoimmune renal
diseases. The initiating pathophysiologic event in acute glomer-
ulonephritis is usually the intraglomerular deposition of immu-
noglobulin due to either trapping of circulating immune com-
plexes or interaction of circulating immunoglobulins with
resident or "planted" glomerular antigens [reviewed in 1, 2].
Immunoglobulin deposition triggers the elaboration of an array
of chemoattractants by several mechanisms (Fig. 1). Many
immunoglobulins fix complement and generate C5a (anaphylo-
toxin), a potent chemotactic peptide. Interaction of Fc regions
of immunoglobulins with Fc receptors on resident and infiltrat-
ing phagocytes stimulates the latter to release chemoattractants
such as interleukin-8 (IL-8), granulocyte-macrophage colony-
stimulating factor (GM-CSF), monocyte chemotactic peptide- 1
(MCP-l), tumor necrosis factor (TNF), and leukotriene B4
(LTB4). Mesangial cells also express Fc receptors and generate
MCP-1 and probably other chemoattractants by a similar mech-
anism [3, 4]. Most chemoattractants, in addition to stimulating
chemotaxis, also provoke phagocyte adhesion to endothelial
cells and diapedesis to the extravascular space. Phagocytosis is
probably less efficient in autoimmune diseases because the
inciting antigens are often either fixed to, or form an intrinsic
part of the host tissue. As a result, reactive oxygen species,
proteolytic enzymes and other cytotoxic molecules are released
to the extracellular space where they disrupt renal architecture
and impair function (so-called "frustrated phagocytosis").
The critical role of adhesion in normal phagocyte trafficking
was originally demonstrated in dramatic fashion in children
with congenital deficiency of the CDI 1ICD18 family of leuko-
cyte adhesion molecules (leukocyte adhesion deficiency (LAD)
type 1) [reviewed in 7]. These unfortunate children suffer
recurrent life-threatening bacterial infections characterized by
systemic neutrophilia and absence of pus formation in infected
tissue due to failure of neutrophils to migrate from blood to the
extravascular space. Since this pioneering discovery, several
other families of adhesion molecules have been characterized
on leukocytes or parenchymal cells which regulate leukocyte
trafficking in health and disease [reviewed in 5—14].
Classification, structural characteristics, cellular distribution,
and cognate ligands of major leukocyte adhesion molecules
Recent evidence from several laboratories, derived princi-
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pally from in vitro studies, suggests that phagocyte adhesion is
mediated, in large part, by the coordinated interactions of four
classes of adhesion molecules: selectins, carbohydrate-contain-
ing selectin ligands, integrins, and immunoglobulin-like (Ig-like)
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Fig. 1. Overview of the recruitment of phagocytic leukocytes during glomerular inflammation. Abbreviations are: TNF, tumor necrosis factor;
PAF, platelet activating factor; IL-8, interleukin-8; LTB4, leukotriene B4; MCP-1, monocyte chemotactic peptide-l; C5a, fifth component of
complement (anaphylotoxin).
molecules (Fig. 2) [reviewed in 5—14]. The initial attachment of
phagocytes to endothelium appears to involve interaction of
phagocyte or endothelial cell selectins with cognate carbohy-
drate-containing ligands [5, 10, 11]. Selectin-mediated adhesion
is relatively resistant to shear stress, but insufficient to immo-
bilize phagocytes on endothelium [5, 10, 11]. Rather, it causes
them to roll on endotheliurn, where they are subject to local
activation signals from endothelium and extravascular tissue
(vide infra). These events facilitate activation of phagocyte
integrins, immobilization of phagocytes by interaction of inte-
grins with Ig-like molecules on endothelium, and migration to
the interstitium [5—9, 12—14].
Selectins
Three selectins have been characterized and named, by
agreement of most major investigators in this field [15], accord-
ing to their cell of original discovery: P-selectin (platelet selec-
tin), E-selectin (endothelial cell selectin), and L-selectin (leu-
kocyte selectin) (Table 1). Selectins share several structural
features: an N-terminal C-type lectin domain, an epidermal
growth factor-like domain, several consensus repeats that share
homology with complement regulatory proteins, a single trans-
membrane domain and a short intracellular C-terminal domain
(Fig. 3) [5, 9—11]. The genes encoding P-, E-, and L-selectin
have been localized to the long arm of chromosome I and lie in
close proximity to the genes encoding complement binding
proteins [10, 11]. The lectin domains of selectins share >60%
homology. Selectins contain between 7 to 12 potential sites for
N-linked glycosylation and it is estimated that glycosylation
accounts for >30% of their mass. The biochemical structure
and functional significance of these carbohydrate residues has
not been elucidated. Selectins support leukocyte-endothelial
cell and leukocyte-platelet adhesion (Table 1). L-selectin is
constitutively expressed by most leukocytes, but not by other
cell-types [5, 10, 11]. Endothelial cells of high endothelial
venules of lymph nodes constitutively express ligands for
L-selectin (lymphocyte homing receptors), and L-selectin plays
a central role in normal recirculation of lymphocytes. Endothe-
hal cells from other vascular beds [10, 111, including glomerular
capillary endothelial cells [16], also support L-selectin-medi-
ated adhesion after exposure to cytokines. P-selectin is ex-
pressed by endothelial cells and platelets (Table 1) [5, 10, 111.
Most P-selectin is stored in intracellular granules and mobilized
to the surface upon cell activation where it supports adhesion of
granulocytes, monocytes and some lymphocyte subsets. E-se-
lectin is expressed, probably exclusively, by cytokine-activated
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Fig. 2. Role of adhesion molecules in the recruitment of phagocytes to extravascular sites of inflammation: Coordinated interaction of selectins,
carbohydrate-containing ligands for selectins, integrins, and immunoglobulin-like molecules. The initial adhesion of circulating phagocytes and
endothelial cells appears to involve the interaction of phagocyte or endothelial cell selectins with carbohydrate-containing ligands. These
interactions cause phagocytes to roll on endothelium and facilitate their immobilization by interaction of phagocyte integrins with Ig-like molecules
on endothelium. In keeping with this hypothesis, phagocytes roll on artificial surfaces coated with P- and E-selectin in vitro, anti-selectin mAb
inhibit phagocyte adhesion and rolling under simulated flow conditions in vitro, and in ex vivo models of the microcirculation, and leukocyte rolling
is not observed in mice in whom the genes for either L- or P-selectin have been deleted by homologous recombination. The molecular basis for
diapedesis has not been established fully, but may involve the interaction of phagocytes with PECAM-1, an Ig-like molecule localized at
intercellular junctions.
endothelial cells and supports adhesion of granulocytes, mono-
cytes, some memory T-lymphocytes, and natural killer cells
(Table 1) [5, 10, 11].
Carbohydrate-containing selectin ligands
Selectins bind at least three broad categories of natural or
synthetic carbohydrates through their NH2-lectin domain: (1)
sulphated polysaccharides such as GIyCAMs (mucins); (2)
oligosaccharides such as sialyl Lewis" (sLe"); and (3) soluble
phosphorylated mono- and polysaccharides (Table 1) [5, 10,
11]. The roles of sLex and GIyCAM-1 as ligands for selectins
have received most attention. Sialyl Lewis" is a sialylated,
fucosylated cell surface tetrasaccharide (Fig. 3) that can be
presented by a variety of proteins and appears to be an
important ligand for both E-selectin and P-selectin. A recent
report indicates that congenital deficiency of sLe", as with
deficiency of CD1 1/CD 18 integrins, is associated with defective
phagocyte trafficking and impaired host defence against infec-
tion (LAD type 2) [171. The endothelial cell ligands for L-selec-
tin are less well-defined and have been the subject of heated
debate [5, 10, 11, 18, 19]. L-selectin may present sLex to
P-selectin and E-selectin under certain experimental conditions
[18]; however, this interaction probably plays a relatively minor
role in L-selectin-mediated adhesion. Recent studies have iden-
tified a novel sulphated, fucosylated, and sialylated 50-kD 0-
glycosylated mucin G1yCAM- 1 as a ligand for L-selectin on high
endothelial venules of lymph nodes [19]. This ligand may
regulate normal recirculation of lymphocytes through lymph
nodes in vivo. The ligands which support L-selectin-mediated
phagocyte adhesion to cytokine-activated endothelial cells from
other vascular beds have not been characterized fully. Func-
tional studies suggest that the glomerular ligand is a glyco-
sylated, sialated molecule and thus shares some biochemical
characteristics with those expressed by lymph nodes and large
vessel endothelial cells [161.
Inte grins
As discussed above, selectin-mediated adhesion facilitates
the immobilization of phagocytes by interaction of phagocyte
integrins with immunoglobulin-like molecules on endothelium
(Fig. 2). Integrins are heterodimeric glycoproteins composed of
non-covalently associated a and f3 subunits (Fig. 3) [5—7].
Integrins mediate diverse cell-cell and cell-matrix interactions
and are classified according to the structure of their /3 subunits.
In general, members of each class share a common /3-subunit
and are distinguished by their unique a-subunits, although there
are some exceptions. The integrins which appear most impor-
tant in leukocyte-endothelial adhesion are the very late activa-
tion antigen-4 /31 integrin (VLA-4) and the CD11/CD18 /3-2
integrins (Fig. 3).
VLA-4 is constitutively expressed by lymphocytes, mono-
cytes, basophils, and eosinophils, but not neutrophils (Table 1).
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Fig. 3. Some structural characteristics of the major families of leukocyte adhesion molecules. Abbreviations are: EGF-like, epidermal growth
factor-like domain; CR-like, complement regulatory protein-like domain; sLex, Sialyl Lewis'; Ig-like, immunoglobulin-like; D, domain,
VLA-4 is a ligand for the inducible Ig-like vascular cell adhesion
molecule-i (VCAM-1) and also mediates cell attachment to
fibronectin and possibly other matrix components. Three f3-2
integrins have been characterized [reviewed in 5—7].Since these
molecules are known by several different pseudonyms (Table
1), most authorities advocate the use of cluster designation
(CD) nomenclature for purposes of uniformity. Accordingly,
these molecules should be referred to as CD! laJCDi8, CDL lbI
CD18 and CD1LcICD18; CD11 and CD18 being the a and f3
subunits, respectively (Fig. 3). CD18 is encoded by a single
gene on chromosome 21 and is a 678 amino acid protein
comprised of a short cytoplasmic tail which contains several
potential phosphorylation sites, a highly conserved transmem-
brane domain, and a longer extracellular region which contains
a conserved cysteine-rich region that is neccessary for surface
expression (Fig. 3). CDZ1a, CD1Zb, and CDI!c are comprised
of 1063, 1136, and 1144 amino acids, respectively, and are
encoded by distinct genes in a cluster on chromosome 16.
Notable structural features on CD 11 subunits include short
nonhomologous cytoplasmic regions containing potential phos-
phorylation sites, highly conserved transmembrane regions,
and a longer extracellular region which contains several cation-
binding repeats, and an "I" (interactive) domain which is
relatively highly conserved across integrin subfamilies and may
be an important adhesion domain (Fig. 3). CD! la shares 36%
homology with CD! lb and CD1 ic and is constitutively ex-
pressed by granulocytes, monocytes and lymphocytes (Table
1). In contrast, CD!lb and CD11c share 63% homology and are
cytes (Table 1). The major ligands for CD! 1aJCD18 are the
Ig-like intercellular adhesion molecules 1 and 2 (ICAM-l and
ICAM-2). ICAM-! is also a ligand for CD1 lb/CDI8; however,
the latter also supports phagocyte adhesion to cellular and
acellular substrates by ICAM- 1 independent mechanisms (Ta-
ble 1). Other ligands for CD! !b/CD18 include fibrinogen, clot-
ting factors and complement fragments (C3b1). The biochemical
structure of the cognate ligand(s) for CDI lc/CD!8 and precise
role of this molecule in leukocyte migration has not been
defined.
Ig-like molecules
ICAM-!, ICAM-2 and VCAM-! are members of the immu-
noglobulin superfamily (Fig. 3) [5, 8, 9, 13]. Other members
include immunoglobulin itself, the T-cell receptor/CD3 com-
plex, CD4, CD8, and class I and class II MHC molecules. These
molecules contain one or more Ig-like regions, each consisting
of a disulphide-bridged loop containing antiparallel 13-pleated
strands arranged into two sheets, a transmembrane domain and
a short cytoplasmic tail. ICAM- 1 is a glycoprotein of molecular
weight 76—114 kD which contains five tandem immunoglobulin
domains and, as discussed above, is a ligand for CDL !a/CD18
and CD11b/CD18, but not CD1!c/CD!8. ICAM-l is constitu-
tively expressed by endothelial cells, and its expression can be
induced on other cell types such as mesangial cells and epithe-
ha! cells by cytokines (vide infra). ICAM-l is also expressed by
lymphocytes and some other leukocytes. Indeed, homotypic
Lectin
EGF-Iike
L-Selectin E-Selectin P-Selectin
ICAM-1
ibraneJmic
ICAM-2 VCAM1*
expressed by granulocytes and monocytes, but not lympho- and heterotypic lymphocyte adhesion mediated by interaction
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Table 1. Classification, cellular distribution, ligands and target cells for major leukocyte adhesion molecules
of ICAM-l and CDI 1aJCD18 facilitates other important lym-
phocyte functions including antigen recognition, lymphocyte
co-stimulation and cytotoxicity.
ICAM-2 is a glycoprotein of molecular weight 60 kD and is a
homolog of ICAM-l characterized by two extracellular Ig-like
domains (Fig. 3). ICAM-2, like ICAM-l, is constitutively ex-
pressed by endothelial cells, lymphocytes and some other
leukocytes and appears to play a role in both leukocyte traf-
ficking and lymphocyte activation. In contrast to ICAM- 1,
endothelial cell levels of ICAM-2 are not influenced by cyto-
kines. As discussed above, ICAM-2 is also a ligand for CD1 lal
CD18, but not other 2 integrins (Table 1).
VCAM-l is a 110 kD glycoprotein that contains seven Ig-like
domains (Fig. 3) [5, 8, 13]. A second form of VCAM-l,
consisting of six Ig-like domains, is generated in some tissues
by alternate splicing [20]. The former predominates in endothe-
hal cells and the functional significance of the latter is unclear.
VCAM-l is constitutively expressed at low levels by endothe-
lials cells and can be induced on endothelial cells and other
cell-types by cytokines (vide infra). VCAM-l supports adhesion
of eosinophils, basophils, monocytes and lymphocytes, but not
neutrophils, through interaction with VLA-4. Accordingly, it
has been suggested that the interaction of VLA-4 and VCAM-l
may be important in the pathophysiology of allergic and delayed
hypersensitivity reactions. Recent studies suggest that another
Ig-like molecule PECAM-! is expressed preferentially at tight
Major Ligands on target
families Individual members Alternate nomenclature Cellular distribution cells Target cells
Selectins L-selectin Leukocytesa Endothelial cells, ?other
Carbohydrate
ligands for
selectinsd
Integrins VLA-4 (13-i)
Ig-like
LAM-I, LECCAM-!, Glycoproteins and
MEL-14, Leu-8, TQI glycolipids (sLe",
DREG.56 sLea, G1yCAM-i,
fucoidin,
?MadCAM-i, ?E-
& P-selectin)
P-selectin CD62, GMPI4O,
PADGEM,
LECCAM-3
Plateletsa and
endotheliala
Glycoproteins and
glycolipids (Lex
sLe", sLea,
fucoidin)
Granulocytes, monocytes
T-cell subsets, some
cancer cells
E-selectin ELAM-!, LECCAM-2 Endothelialb Glycoproteins and
glycolipids (sLe",
sLea, ?L-selectin)
Neutrophils, monocytes,
lymphocyte subsets,
some cancer cells
Sulphated polysaccharides SgpSO, mucin-like Endothelium L-selectin Lymphocytes, ?other
(G1yCAM- I)
Oligosaccharides (sialyl sLex Granulocytes, E-selectin and P- Endothelium and platelets
lewis")
LPAM-2
monocytes,
lymphocytes
Monocytes,a
lymphocytes,"
eosinophils"
selectin
VCAM-l,
Fibronectin
Endothelium, epithelial,
mesangial, vascular
smooth muscle
CD1 iaJCDl8 (13-2) LFA-l, TA-i Leukocytes" ICAM-i, ICAM-2 Endothelial," epithelial,
mesangial, vascular
smooth muscle
CD1 lb/CD18 (13-2) Mac-i, Mo!, OKM1,
gpl6O
Granulocytes,"
monocytesa
ICAM-I, C3bi,
fibrinogen, factor x
other
Endothelial, epithelial,
mesangial, vascular
smooth muscle,
acellular surfaces
CD! ic/CD18 (p3-2) p150, 95, LeuM5 Granulocytes,a
monocytes"
Not characterized Endothelial, mesangial
ICAM-I CD54 Endothelial,c
epithelial,"
mesangial,b
smooth muscle,b
some cancer cells
CD! la/CD18,
CDI lb/CD 18
Most leukocytes
ICAM-2 Endothelial CD! ia/CDL8 Most leukocytes
VCAM-i INCAM 110 Endothelial,"
epithelial,"
mesangia!,"
smooth muscle"
VLA-4 Monocytes, lymphocytes,
eosinophils
PECAM-! EndoCAM, CD3! Endothe!ia!,e
plateles, some
leukocytes
PECAM-1 Some leukocytes,
endothelia!, platelets
"Rapid change in avidity and/or surface expression upon stimulation of cellsb Absent or expressed at low levels unless exposed to cytokines
Constitutive expression and further induction by cytokinesd Relative contributions of these molecules to selectin-mediated adhesion has yet to be defined
Particularly at intercellular junctions.
1290 Brady: Leukocyte adhesion molecules
Table 2. Mechanisms of regulation of leukocyte adhesion by chemoattractants and cytokines
Response time Sites of action Mechanisms Molecules Stimuli Inhibitors
Seconds-minutes
Hours-days
Leukocytes
Platelets
Endothelial
Mesangial
Leukocytes
Endotheial
Mesangial, epithelial,
smooth muscle,
and cancer cells
Increase in avidity and/or
expression of preformed
adhesion molecules
Increased expression of
preformed adhesion
molecules
Increased expression of
preformed adhesion
molecules
Increase in cell adhesiveness
De novo synthesis of adhesion
molecules
De novo synthesis of adhesion
molecules
De novo synthesis of adhesion
molecules
CDI l/CD18, VLA-4,
L-selectin
P-selectin
P-selectin
?Ligand(s)
CD1 l/CD18, L-
selectin
ICAM-l, VCAM-I,
E-selectin, ligands
for L-selectin, ?P-
selectin
ICAM-I, VCAM-I
C5a, LTB4, PAF,
IL-8, MCP-l,
TNFa, bacterial
wall peptides,
E-selectin,
ANCA
ADP, thrombin,
histamine
Histamine,
thrombin, H202,
MAC, LTC4
LTD4
GM-CSF
TNFa, IL-l/3, IF-y
IL-4, endotoxin
TNFa, IL-I f3, IF-y
IL-4, endotoxin
15-HETE, EDRF,
PG!2 epinephrine,
lipoxins, IL8a
Lipoxins
TGF
Abbreviations are: LT, leukotriene; PAF, platelet activating factor; IL, interleukin; MCP, monocyte chemotactic peptide; TNF, tumor necrosis
factor; HETE, hydroxyeicosatetraenoic acid; PG!2. prostacycin; ADP, adenosine diphosphate; H202, hydrogen peroxide; MAC, membrane
attack complex of complement; GM-CSF, granulocyte macrophage colony-stimulating factor; IF, interferon; TGF/3, transforming growth factor
beta; ANCA, anti-neutrophil cytoplasmic antibody.
a IL-8 may promote or inhibit leukocyte-endothelial cell adhesion depending on the experimental conditions.
junctions of endothelial cells and and may be a critical regulator
of phagocyte diapedesis between endothelial cells [21].
Regulation of adhesion by chemoattractants and cytokines
The maintainence of phagocytes and endothelium in an
inactive "anti-adhesive" phenotype is critical in preserving the
integrity of the microvasculature in health. In disease, inflam-
matory mediators regulate adhesion by altering the avidity
and/or expression of preformed molecules for cognate ligands,
and by influencing de novo synthesis of adhesion molecules
(Table 2). It is probable that the initial recruitment of phago-
cytes is achieved by the former mechanism and that subsequent
adhesive interactions are modulated through the latter.
Rapid-acting stimulators of adhesion
Chemoattractants (C5a, LTB4), cytokines (MCP-l, IL-8,
GM-CSF, TNFa), membrane associated molecules (PAF,
E-selectin) and some anti-neutrophil cytoplasmic antibodies
(ANCA) rapidly enhance phagocyte adhesiveness for endothe-
hal cells [5—7, 23], including glomerular endothelial cells [73,
80], mesangial cells [30, 31, 76, 77], and a variety of other
substrates by increasing the avidity of constitutively expressed
CDI 1/CD 18 integrins and/or L-selectin for cognate ligands.
Most of these mediators also provoke rapid mobilization of
preformed CD1 lb/CD 18 and CD! lc/CD1 8 from intracellular
sites to the cell surface; however, a quantitative change in
expression does not appear to be a prerequisite for increased
adhesion [5—7]. Chemoattractants may be relatively neutrophil-
specific (such as IL-8) or monocyte-specific (such as MCP-1)
and the composition of leukocyte infiltrates is likely deter-
mined, at least in part, by the relative concentrations of
different mediators at sites of inflammation. Other mediators,
such as thrombin, histamine, leukotriene C4 (LTC), reactive
oxygen species and the membrane attack complex of comple-
ment (MAC) increase endothehial cell adhesiveness for phago-
cytes by mobilizing preformed P-selectin from intracellular
Weibel-Palade bodies to the surface of endothehial cells [5, 10,
11]. L-selectin and P-selectin are shed rapidly from phagocytes
and endothelial cells, respectively, following cell activation, a
process that may limit adhesion and facilitiate diapedesis in
vivo. An in depth discussion of the signal transduction events
which mediate activation of phagocytes and endothehium under
these circumstances is beyond the scope of this review. Most
stimuli for phagocyte activation interact with stimulus-specific
cell surface receptors and initiate a cascade of events which
include activation of phosphohipase C through guanine nude-
otide regulatory proteins/tyrosine kinase activity, hydrolysis of
phosphatidyinositol bisphosphate and generation of inositol
trisphosphate and diacylglycerol, elevation of intracellular cal-
cium concentration, and activation of protein kinase C [re-
viewed in 5, 22]. The distal signal transduction events that
ultimately enhance the avidity of adhesion molecules for higands
are unknown, but probably involve phosphorylation of adhe-
sion proteins and/or cytoskeletal elements [reviewed in 5]. The
molecular basis for mobilization of P-selectin has been studied
less extensively, but appears to be calcium and phosphoryla-
tion-dependent.
Induction of adhesion molecule synthesis by cytokines
Prolonged exposure of phagocytes, endothelial cells, and
other resident tissue cells to cytokines promotes adhesion by
stimulating synthesis of adhesion molecules (Table 2)[5, 8—14].
Cytokines also promote extravasation of phagocytes by induc-
ing endothehial cell synthesis of IL-8, MCP-l and PAF, and by
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provoking rearrangement of the endothelial cell cytoskeleton
[reviewed in 8]. The profile of adhesion molecules expressed
after exposure to cytokines may differ dramatically depending
on the cytokine, cell-type, and duration of exposure. GM-CSF
enhances the synthesis of CD1 1/CD 18 and L-selectin by phago-
cytes and their precursors. TNFa, IL-lp and y-interferon
enhance ICAM-1 synthesis by endothelial cells [reviewed in 5,
8, 121, including glomerular endothelial cells [73, 801, and
induce de novo synthesis and expression of ICAM-1 by glomer-
ular mesangial cells [76], and renal tubular epithelial cells [58,
63, 68, 79]. In general, peak expression of ICAM-1 is observed
after 24 hours exposure and maintained for at least 72 hours.
TNF and IL-1/3 also induce VCAM-1 synthesis by glomerular
endothelial [72], mesangial [64, 65], and tubular epithelial cells
[64] with similar kinetics to ICAM- 1. In contrast, these cyto-
kines induce transient expression of E-selectin by endothelial
cells that peaks after four hours and is virtually undetectable
after 24 hours [5, 10—12, 69, 72]. Endothelial cells are then
refractory to reinduction of E-selectin by the same cytokine,
but respond to other cytokines. Interestingly, E-selectin ex-
pression by endothelial cells is also induced by yinterferon, but
not interleukin-4 [5], while VCAM-l levels on endothelial and
mesangial cells are enhanced by interleukin-4, but not y-
interferon [5, 65]. As discussed above, TNFa also induces
expression of a ligand for L-selectin on endothelial cells cul-
tured from glomeruli [16] and larger blood vessels [5, 10, 11].
Non-endothelial cells do not appear to express selectins or
support L-selectin-mediated adhesion even after activation by
cytokines. These observations are consistent with the notion
that selectin-mediated adhesion is a specialized function that
evolved to tether leukocytes to endothelium under conditions of
shear stress.
The molecular basis for this differential regulation of adhe-
sion molecule expression has not been defined. Cytokine-
induced expression of ICAM-1, VCAM- 1 and E-selectin is
transcriptionally regulated and a variety of potential regulatory
sequences have been identified in the 5' flanking regions of their
genes [reviewed in 5, 8]. Most cytokines interact with specific
cell surface receptors [8]. The signals which transduce receptor
binding to activation of transcription are the subject of intensive
investigation. Putative mechanisms include activation of intra-
cellular transcriptional regulatory proteins (such as NFKB) by
protein kinases, reactive oxygen species or membrane lipids,
and direct translocation of cytokine-receptor complexes to the
nucleus [51. The elucidation of these events may suggest
strategies for inhibition of synthesis of specific adhesion mole-
cules during inflammation.
Rapid-acting inhibitors of adhesion
Given that many inflammatory diseases are self-limiting, it is
likely that endogenous compounds exist that inhibit phagocyte
adhesion. Several candidate molecules have already been iden-
tified (Table 2). Nitric oxide, a potent vasodilator and inhibitor
of platelet aggregation, also attenuates neutrophil adhesion in
vitro [25] and in vivo [26], raising the possibility that this
compound may be a tonic inhibitor of phagocyte-endothelial
cell interaction. Indeed, the recent discovery of a cytokine-
inducible form of nitric oxide synthetase in endothelium and
other cell-types [8] suggests that this compound may also
regulate phagocyte recruitment during inflammation. Several
eicosanoids also attenuate adhesion in experimental models of
inflammation. These include prostacyclin (PGI2), lipoxin A4
(LXA4), and 15-hydroxyeicosatetraenoic acid (15-HETE) [27-.
37]. P012 synthesis, like nitric oxide synthesis, is generated by
endothelial cells under basal conditions and in increased quan-
tities following activation by cytokines [8]. This compound is a
potent inhibitor of neutrophil-endothelial cell adhesion, proba-
bly by increasing cyclic AMP levels in neutrophils [27]. LXA4 is
generated by phagocytes alone via the sequential actions of 15-
and 5-lipoxygenases on arachidonic acid [28], and during phago-
cyte-platelet interaction via the sequential actions of phagocyte
5-lipoxygenase and platelet l2-lipoxygenases [29]. LXA4 is a
potent inhibitor of several leukotnene-induced responses in-
cluding LTD4-induced phagocyte-mesangial cell adhesion [30,
31], LTB4-induced chemotaxis [33], and, under certain circum-
stances, LTB4-induced phagocyte adhesion and migration
across endothelium [34]. 15-HETE is generated by a variety of
cells through the actions of 15-lipoxygenases, cyclooxygenase
and epoxygenases on arachidonic acid [35], and is rapidly
esterified into phagocyte phospholipid pools. Esterified 15-
HETE markedly attenuates phagocyte adhesion induced by
LTB4 and other receptor-mediated stimuli by lowering the
affinity of phagocyte cell surface receptors for their cognate
ligands [36, 37]. These observations raise the possibility that
15-HETE and the lipoxins may have anti-inflammatory activity
in vivo, and suggest that products of the 5-lipoxygenase (LT)
and 15-lipoxygenase pathways (15-HETE, LX) may exert
counter-regulatory influences on leukocyte-endothelial cell ad-
hesion. In support of this hypothesis, relatively high concentra-
tions of LXA4 and 15-HETE have been reported in several
human diseases [35, 38], and administration of exogenous
iS-HETE attenuates injury in several models of inflammation
[35, 38].
Inhibition of adhesion molecule synthesis by cytokines
Prolonged exposure of endothelial cells to certain cytokines
may also reduce their adhesiveness for leukocytes or modulate
the actions of other cytokines [reviewed in 5]. Transforming
growth factor beta (TGFI3), for example, diminishes basal
endothelial ahesiveness for phagocytes. In addition, TGF$
blunts the pro-adhesive effects of TNFa and IL-1$ on endothe-
hum, an action that may involve inhibition of E-selectin expres-
sion. IL-4, a potent inducer of endothelial VCAM-1 expression,
attenuates ICAM-1 and E-selectin expression by these cells.
The relevance of these findings in vivo has yet to be established.
However, it seems reasonable to conclude that the profile of
adhesion molecules expressed by resident tissue cells during
inflammation reflects the complex interplay of pro- and anti-
adhesive cytokines, and is determined not just by the relative
concentrations of these compounds, but also by the duration of
exposure. Further characterization of the endogenous inhibi-
tors of adhesion, and the elucidation of their mechanisms of
action may prove fruitful in defining novel approaches to the
treatment of inflammation.
Renal expression of leukocyte adhesion molecules in health and
disease
ICAM-1, VCAM-1 and E-selectin in normal kidneys
ICAM-1 is normally expressed at low levels by endothehial
cells of large vessels, glomeruli, and peritubular capillaries, and
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Table 3. Expression of leukocyte adhesion molecules in healthy and diseased kidneysa
Site of
expression
ICAM-l VCAM-l E-selectin
Normal Disease Normal DiseaseNormal Disease
Endothelium larger vessels
glomerular
pentubular
+ +/++
+ +/++
+ +/++
—1+ ++
— +
—1+ -t-+
—
—1+
—
—1+
—
—1+
Epithelium
Mesangium
Bowman's capsule
Tubule epithelium
+ ++
— + +
—1+ + +
+ ++
— + +
— + +
— —
— —
— —
Interstitium —1+ + + — + — —
Diseases Necrotizing GN
Crescentic GN
MPGN
IgA nephropathy
Focal segmental GS
Minimal change
Membranous
Lupus nephritis
Mixed essential cryo
Henoch-Schönlein
Interstitial nephritis
Allograft rejection
Necrotizing GN
Crescentic ON
IgA nephropathy
Minimal change
Lupus nephritis
Interstitial nephritis
Diabetic nephropathy
Amyloid
Gout
Allograft rejection
Acute GN
Endotoxic shock
Lupus nephritis
IgA nephropathy
Allograft rejection
References 14, 39—62, 81—87 14, 59, 60, 63—68, 81 14, 59, 60, 69—72, 81
Symbols are: —, not detected; —1+, detected by some, but not all investigators; +, expression consistently reported; ++ marked increase in
expression. Abbreviations are: GN, glomerulonephritis; MPGN, membranoproliferative glomerulonephritis; OS, glomerulosclerosis; Cryo,
cryoglobulinemiaa There are few published reports of the expression of ICAM-2, P-selectin or ligands for L-selectin in renal tissue. PECAM-l appears to
constitutively expressed by all renal vascular endothelium (not shown here).
by mesangial cells, some parietal epithelial cells of Bowman's
capsule, and occasional interstitial cells (Table 3) [39—62, 81—
87]. In contrast, constitutive VCAM-1 is usually only found on
parietal epithelial cells of Bowman's capsule, and occasional
endothelial cells of large vessels or pentubular capillaries [59,
60, 63, 66, 67]. E-selectin is not constitutively expressed in the
kidney [14, 59, 60, 69—72].
ICAM-1 in kidney diseases
Striking changes in ICAM- 1 expression have been reported in
glomerulonephritis, tubulointerstitial inflammation, and renal
allograft rejection (Table 3) [39—62, 81—87]. Increased glomeru-
lar expression of ICAM- 1 is a common finding in patients with
active crescentic glomerulonephntis, mesangioproliferative gb-
merulonephntis, IgA nephropathy, Henoch-Schönlein purpura,
and proliferative grades of lupus nephritis [40-45]. De novo
expression of ICAM-1 by proximal tubules cells, particularly at
the luminal membrane, and increased expression by interstitial
cells are common additional findings in these diseases [40—45].
In general, the intensity of staining correlates with disease
activity. Gbomerular ICAM-1 may revert towards basal levels
or even be reduced in patients with advanced sclerotic disease.
In contrast to these proliferative forms of glomerulonephritis,
glomerular and tubulointerstitial ICAM-1 levels are usually
unchanged or reduced in patients with minimal change disease
[41]. Variable expression of ICAM-l has been reported in
patients with focal segmental glomeruloscierosis and membra-
nous nephropathy [41—43]; some investigators reporting in-
creased mesangial and/or tubulointerstitial staining [41, 43], and
others reporting a focal and segmental decrease in glomerular
expression [42]. The reason for these disparities is unclear, but
may reflect sampling at different stages in the disease process.
Soluble forms of many adhesion molecules, including ICAM-l
[49, 50], circulate normally in blood. An intriguing preliminary
report suggests that circulating levels of ICAM-1 are elevated in
some forms of acute glomerulonephritis [50]. It will be of
interest to determine the source of circulating ICAM- 1 under
these circumstances and whether changes in circulating levels
of adhesion molecules represent another mechanism of regula-
tion of leukocyte adhesion during inflammation.
A different pattern of expression of ICAM-1 has been re-
ported in renal biopsy specimens from patients with allograft
rejection [52—62]. Glomerular levels of ICAM-1 are usually
unchanged in this setting. In contrast, there is frequently
dramatic up-regulation of ICAM-l expression on proximal
tubule cells, particularly on the luminal membrane, and on
some distal tubule and collecting duct cells, and infiltrating
leukocytes. Tubular staining is usually most pronounced in
areas of intense leukocyte infiltration. Most investigators have
found it difficult to assess changes in ICAM-l levels on vascular
endothelium in rejection due to the constitutive expression of
ICAM-1 at this site. Circulating levels of ICAM-l are also
increased during acute rejection, but not cyclosponne toxicity,
and this parameter has been proposed as a means of differen-
tiating these two common diagnoses [62]. ICAM-1 levels have
not been reported in other forms of tubulointerstitial inflamma-
tion in humans; however, a marked increase in proximal tubule
and interstitial staining has been observed in a munne model of
hereditary tubulointerstitial nephritis [861.
VCAM-1 in kidney diseases
There are few published studies on VCAM-1 or E-selectin
expression in renal inflammation (Table 3). Seron, Cameron and
Haskard assessed VCAM- 1 expression in normal kidneys and
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50 biopsy specimens from patients with a variety of glomerulo-
nephritides or tubulointerstitial diseases [63]. De novo expres-
sion of VCAM- 1 was observed on proximal tubule cells in
virtually all patients with vasculitis and crescentic nephritis,
lupus nephritis (class II, III, IV, and V), IgA nephropathy, and
acute interstitial nephritis induced by nonsteroidal anti-inflam-
matory drugs. VCAM-1 levels were highest in patients with
vasculitis, and there was a weak positive correlation between
the level of expression and the intensity of the leukocytic
infiltrate. VCAM-l expression was not observed on vascular
endothelial cells in any disease, even in the presence of a
marked inifitrate. Interestingly, striking proximal expression of
VCAM-l was also observed in proximal tubules of patients with
diabetic nephropathy, amyloid, gouty nephropathy, minimal
change disease, and membranous nephropathy; diseases that
are not usually associated with leukocytic infiltration of kidney
[631. Increased renal VCAM-l expression has also been re-
ported in experimental nephrotoxic serum nephritis [811 and the
MRL-/pr murine model of lupus nephritis [64]. The latter model
is characterized by dramatic induction of VCAM- I expression
in cortical, but not medullary tubule epithelial cells. In addition,
there was a marked increase in VCAM-1 expression on vascular
endothelium and in the glomerular mesangium. VCAM-l levels
correlated directly with the activity of disease, as determined
by proteinuria and histologic assessment, and the intensity of
the associated leukocytic infiltrate [64]. Furthermore, kidney
tissue sections from nephritic mice supported adhesion of T-cell
and macrophage cell-lines, a process that was inhibited by
monoclonal antibodies against VCAM-l and ICAM-l. These
data provided further evidence that these molecules contribute
to leukocyte recruitment, and are not merely markers for
cytokine release by infiltrating leukocytes. The stimulus for
induction of ICAM-1 and VCAM-1 on tubular epithelium in
patients with glomerulonephritis is unclear. Potential mecha-
nisms include primary involvement of the tubulointerstitium
and/or the "down-stream" actions of glomerular cytokines that
reach the tubulointerstitium via blood, urine, or diffusion
through extravascular tissue. In support of the former hypoth-
esis, T-cells cloned from inflammatory renal infiltrates in exper-
imental lupus nephritis demonstrate specific autoreactivity
against renal tissue and induce ICAM-1 and MHC class II
molecules on cultured tubule epithelial cells [48]. The latter
process appears to be due, at least in part, to the actions of
interferon-y, as induction can be blocked by monoclonal anti-
body against this cytokine [48].
Several investigators have reported de novo expression of
VCAM- 1 on proximal tubule cells and occasional distal tubules
in renal allograft rejection in humans [59, 60, 66—68]. VCAM-1
expression is usually focal under these circumstances (30 to
50% of tubules) and most pronounced in areas of leukocyte
infiltrates. In addition, VCAM-l tends to be expressed in a
patchy distribution within individual tubules and concentrated
towards the basolateral surface. Striking induction of VCAM-1
is usually observed on the endothelium of peritubular capillar-
ies, venules, and arterioles, but not glomeruli, in areas of
leukocytic infiltrates.
E-selectin in kidney diseases
The pattern of expression of E-selectin in renal disease is
largely undefined. Cytokine-activated renal microvascular en-
dothelial cells clearly express E-selectin in vitro [69, 72]. A
preliminary report suggests that E-selectin is expressed de novo
by glomerular endothelial cells in some patients with acute
glomerulonephritis, lupus nephritis, and IgA nephropathy, but
not in patients with focal segmental glomeruloscierosis or
membranous nephropathy [51]. Induction of E-selectin on
endothelial cells of interstitial venules is a frequent additional
finding in patients with lupus nephritis and prominant interstitial
inflammation, and in patients with IgA nephropathy during
acute exacerbations [51]. Interestingly, glomerular levels of
E-selectin appear to be highest in patients with high circulating
levels of TNFa [51]. De novo expression of E-selectin on
glomerular endothelium has also been reported in experimental
models of septic shock [70, 71] and acute glomerulonephritis
[81]. In the latter study, glomerular expression of E-selectin,
ICAM- 1 and VCAM- 1 was mimicked by infusion of TNFa, but
not IL-1/3, into the renal artery of normal animals, and was
attenuated in nephntic animals by prior treatment of animals
with a monoclonal antibody against TNFa or soluble recombi-
nant human TNF receptor-i [81]. Taken together, these data
suggest that TNFa may be a major stimulus for induction of
adhesion molecule expression in acute glomerulonephritis.
The distribution of E-selectin on endothelium in acute rejec-
tion tends to parallel that of ICAM-1 and VCAM-l. De novo
E-selectin expression is usually observed on endothelial cells of
peritubular capillaries and large vessels, but not glomeruli, with
highest levels in areas of leukocyte infiltration. However, it
should be noted that induction of E-selectin is not an invariable
in either acute glomerulonephritis [51] or aliograft rejection [66]
in humans. These negative findings may reflect the transience of
E-selectin expression (vide supra) and the absence of staining
does not neccessarily preclude an important role for this
molecule in the early stages of renal inflammation. Alterna-
tively, the absence of E-selectin may reflect extensive endothe-
hal cell injury, as occurs frequently in necrotizing glomerulo-
nephritis and allograft rejection. In support of the latter
explanation, focal absence of PECAM- 1, which is constitu-
tively expressed by healthy renal endothehial cells, has been
reported in biopsies from patients with renal allograft rejection
[60].
Other adhesion molecules
There is little information on the distribution of ICAM-2,
P-selectin, or ligands for L-selectin in renal diseases. It is also
worth noting that few studies have assessed the expression of
ICAM-l, VCAM-l, and E-selectin in the same disease, or
correlated the expression of these molecules with the relative
numbers of different types of leukocytes in inflammatory infil-
trates. It is apparent from the in vivo and in vitro observations
discussed above, that most resident renal cells, in their basal
state or following activation with cytokines, express ligands
that can support granulocyte, monocyte or lymphocyte adhe-
sion. Yet regional differences in the composition of leukocyte
infiltrates are found in many inflammatory renal diseases.
Furthermore, as noted above, enhanced expression of adhesion
molecules has been noted in diseases that are usually not
associated with leukocyte infiltration. These observations fur-
ther suggest that leukocyte recruitment is not regulated solely
by the profile of adhesion molecules on invading and resident
cells, but also by the complex interplay of chemoattractants and
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Platelet
Neutrophil
Endothelial
cell
Fig. 4. Proposed mechanism(s) by which phagocyte adhesion promotes the generation of lipoxygenase products by transcellular routes at sites
of inflammation. Both glomerular endothelial cells and platelets lack 5-lipoxygenase (5-LO) activity, but transform phagocyte-derived LTA4 to
biologically active products. Glomerular endothelial cells conjugate LTA4 with glutathione (GSH) to form LTC4, a reaction catalysed by LTC4
synthetase (glutathione-S-transferase) [73, 74]. Platelets convert LTA4 to both LTC4 and lipoxins (LX) through the actions of LTC4 synthetase and
12-lipoxygenase (12-LO), respectively [29]. MAb which block phagocyte adhesion to glomerular endothelial cells, also block transcellular LTC4
formation during coincubations of phagocytes and glomerular endothelial cells [73, 74]. These observations suggest that adhesion facilitates
transfer of LTA4, an unstable lipophilic and hydrophobic intermediate, from phagocytes to endothelial cells, thereby promoting the generation of
LO products and minimizing non-enzymatic hydrolysis of LTA4 to inactive products in extracellular fluid. Alternatively, or in addition, adhesion
may prime phagocyte lipoxygenase pathways and enhance LTA4 biosynthesis [82]. By inference, agents that block adhesion may inhibit the
generation of lipid mediators at sites of inflammation, in addition to blocking recruitment of phagocytes.
other soluble and cell-associated activation signals within the
local inflammatory milieu.
Adhesion facilitates dynamic interplay between phagocytes and
renal parenchymal cells
Phagocyte adhesion, in addition to facilitating phagocyte
recruitment, may also promote a dynamic interplay between
phagocytes and resident tissue cells that ultimately contributes
to the pathophysiology of renal inflammation. Recent evidence
suggests that adhesion may serve to amplify the concentrations
and array of lipid mediators at sites of inflammation by facili-
tating the generation of eicosanoids by transcellular routes. For
example, neutrophils and endothelial cells, and neutrophils and
platelets effectively pool their enzymatic machinery during
cell-cell interaction to generate lipoxygenase products that
neither cell can generate alone (Fig. 4) [74]. Glomerular endo-
thelial cells lack 5-lipoxygenase activity and generate little, if
any, leukotnenes from arachidonic acid, but can convert neu-
trophil-derived LTA4 to LTC4 during cell-cell interaction [73,
74]. Monoclonal antibodies against CD! 1/CD 18 integrins and
L-selectin block phagocyte adhesion to glomerular endothelial
cells and attenuate LTC4 biosynthesis during concubation of
phagocytes and glomerular endothelial cells [73, 74]. These
observations suggest that adhesion promotes leukotriene syn-
thesis by transcellular routes probably by approximating phago-
cyte and endothelial cell membranes and facilitating the transfer
of the unstable lipophilic intermediate LTA4 between cells
(Fig. 4). In addition, adhesion may prime phagocyte 5-lipoxy-
genase pathways, as with other functional responses (vide
infra), and thus promote LTA4 generation and release by
phagocytes [82].
Adhesion may also promote renal injury by priming phago-
cyte respiratory bursts and degranulation responses to the
actions of chemoattractants and cytokines (Fig. 5) [7, 75—77]. In
keeping with this hypothesis, phagocytes generate greater
quantities of superoxide anion when adherent to cytokine-
activated mesangial cells in vitro, and monoclonal antibodies
(mAb) against CD!8 attenuate adhesion, superoxide anion
generation and mesangial cell injury in this setting [76]. A
preliminary report suggests that CD! 1/CD 18-mediated phago-
cyte adhesion to glomerular basement membrane potentiates
free radical generation in a similar manner [92]. It is probable
that adhesion also promotes glomerular cell injury and disrup-
tion of the filtration barrier by facilitating the release of reactive
oxygen species and proteases in close proximity to glomerular
cells and the glomerular basement membrane, thereby reducing
the effectiveness of extracellular free radical scavengers and
protease inhibitors (Fig. 5) [reviewed in 5].
Monoclonal antibodies against CD1 l/CD18 integrins attenu-
ate lysis of renal tubule epithelial cells by cytotoxic T-lympho-
cytes in vitro [78]. In addition, anti-ICAM-l mAb inhibit antigen
presentation by cytokine-activated renal tubular cells [79] and
mesangial cells in vitro [93]. These observations suggest addi-
tional mechanisms whereby adhesion may contribute to the
Phagocyte
Glomerular
cell
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Degranulation
2
Extracellular inhibitors
Interaction of adhesion molecules
Fig. 5. Proposed mechanisms by which adhesion of phagocytes to glomerular cells promotes glomerular cell injury mediated by reactive oxygen
species and proteases. Adherent phagocytes display enhanced respiratory bursts and degranulation responses when compared to phagocytes in
suspension [75—77]. In addition, adhesion may promote glomerular cell injury by facilitating release of phagocyte-derived cytotoxic molecules in
close proximity to glomerular cell membranes, thereby reducing the effectiveness of extracellular free radical scavengers and protease inhibitors
[5]. Thus, mAb against adhesion molecules, may not only inhibit recruitment of phagocytes, but also phagocyte-mediated glomerular cell injury.
Further discussion is in the text and [5, 7, 75—77].
pathophysiology of acute allograft rejection and glomerulone-
phritis. Taken together, these studies highlight the importance
of adhesion in promoting bidirectional flow of information
between phagocytes and resident tissue cells. Furthermore,
they suggest that inhibitors of adhesion may not only block
recruitment of circulating phagocytes, but also attenuate poten-
tially deleterious interactions between phagocytes and resident
tissue cells at sites of inflammation.
Efficacy of monoclonal antibodies against leukocyte adhesion
molecules in the treatment of renal inflammation
The efficacy of monoclonal antibodies (mAb) against different
adhesion molecules as anti-inflammatory agents has been tested
in experimental models of glomerulonephritis, tubulointerstitial
disease, allograft rejection, and renal ischemia-reperfusion in-
jury (Table 4) [81—911. Mulligan et a! assessed the influence of
mAb against CD18, CD11a, CDI1b, VLA-4, ICAM-l and
E-selectin on glomerular neutrophil accumulation and protein-
uria in Long-Evans rats with nephrotoxic serum nephritis [81].
Their model is characterized by up-regulation of glomerular
ICAM- 1, VCAM- 1 and E-selectin expression, rapid neutrophil
infiltration of glomerular (maximum at 6 hr), and complement-
and neutrophil-dependent proteinuria. Treatment of animals
with mAb against CD18, CD11b, and ICAM-l caused a 63%,
46%, and 55% reduction, respectively, in proteinuria, and a
79%, 66%, and 54% reduction, respectively, in glomerular
neutrophil counts, suggesting a role for these ligands in the
pathogenesis of glomerular inflammation. In contrast, mAb
against CD1 la and E-selectin did not confer protection. Inter-
estingly, mAb against VLA-4 also attenuated neutrophil recruit-
ment and proteinuria in this model, even though this ligand does
not play a direct role in neutrophil trafficking. These observa-
tions suggest that some mAb may protect via mechanisms other
than direct inhibition of neutrophil adhesion (vide infra). This
contention is further supported by studies by Wu et a! that
evaluated the influence of anti-CD 1 lb mAb on glomerular
neutrophil recruitment and proteinuria in nephrotoxic serum
nephritis in Lewis rats [82]. While infusion of anti-CD 1 lb mAb
16 hours prior to induction of disease caused a striking decrease
in both proteinuria and neutrophil infiltration in their study,
administration of mAb 30 minutes before induction also af-
forded protection without affecting glomerular neutrophil
counts. In contrast to these studies in rats, two studies failed to
demonstrate a protective effect of anti-CD18 mAb in nephro-
toxic serum nephritis in rabbits using doses of mAb that
saturate CD18 on circulating and glomerular neutrophils, inhibit
neutrophil migration to other vascular beds, and have been
shown previously to attenuate neutrophil-dependent tissue in-
jury in other organs in this species (Table 4).
MAb against CD1 la and ICAM-l have been reported to
attenuate injury in two studies of crescentic glomerulonephritis
in Wistar-Kyoto rats [84, 85]. This model is characterized by
linear deposition of rat IgG in the glomerular basement mem-
brane, up-regulation of ICAM-1 on glomerular endothelium,
++++ Generation of oxygen radicals
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Table 4. Efficacy of some adhesion-blocking monoclonal antibodies in inflammatory renal diseases and ischemia-reperfusion
Renal disease Species (strain) Molecule Antibody Preparation Dose Timinga Protection Ref
Nephrotoxic serum nephritis Rat (Long- CD18 CL-26 F(ab')2 33 jg i.v. After Yes 81
Evans)
CDlla WT-l Intact 200 sg i.v. Simultaneous No
CDllb IB6c Intact 300 jsg i.v. Not reported Yes
VLA-4 TA-2 Intact 800 sg i.v, Simult + after Yes
ICAM-l lA29 F(ab')2 200 sg i.v. + i.p. After Yes
E-selectin CL-3 F(ab')2 45/133 g i.v. After No
Nephrotoxic serum nephritis Rat (Lewis) CD! lb 0X42 Intact 0.15 mg/lOO g i.v. Before Yes 82
Nephrotoxic serum nephritis
Nephrotoxic serum
Rat (Wistar)
Rabbit (New
Zeajd
ICAM-!
CDI8
ICAM-l
lA29
R15.7
R6.5
Intact
Intact
Intact
5 mg/kg i.v.
2 mg/kg i.v.
2 mg/kg i.v.
Before + after
Before
Before
Yes
No
No
83
d
Nephrotoxic serum nephritis Rabbit (New
Zealand
White)
CDI8 60.3 Intact Saturating dose i.v! Before No
Crescentic glomerulonephritis Rat (Wistar-
Kyoto)
CD! Ia
ICAM-l
CD! Ia +
ICAM-l
WT-l
1A29
WT-1 ÷
1A29
Intact
Intact
Intact
1—5 mg/kg i.p.
1—5 mg/kg i.p.
1 mg/kg of both i.p.
Before + after
Before + after
Before + after
Yes
Yes
Yes'
84
Crescentie glomerulonephritis Rat (Wistar-
Kyoto)
CDI la +
ICAM-l
WT-l +
1A29
Intact 0.5 mg of both i.v.
+ i.p.
Before + after Yes 85
Tubulointerstitial nephritis Mouse (CBA/
Ca, kdkd)
ICAM-1 YNI/l .7 Intact 10 mg/kg/day i.p. After Yes 86
Acute allograft rejection Monkey
(Cynomolgus)
ICAM-l R6.5 Intact 0.01—2 mg/kg/day i.v. Before + after Yes 87
Acute allograft rejection Human ICAM-1 BIRR1 Intact i,v. to achieve serum
levels of —10 g/
ml
Before + after Yes 88
Ischemia-reperfusion Rabbit (New
Zealand
White)
CD18 60.3 Intact 2 mg/kg i.v. Before No 91
Ischemia-reperfusion Rabbit (New
Zealand
White)
CDI8
ICAM-1
R15.7
R6.5
Intact
Intact
2 mg/kg i.v.
2 mg/kg i.v.
Before
Before
No
No
b
a Relative to induction of disease
' Neuringer J, Brady HR, unpublished observations
C Additive protection when compared with equivalent doses of individual mAbd O'Meara YM, Salant DJ, Brady HR and
Tipping P0, Cornthwaite U, Holdsworth SR, XII International Congress of Nephrology, Jerusalem, Israel, June 1993
Dose sufficient to saturate CD18 on circulating and glomerular leukocytes, and cause demargination of leukocytes (leukocytosis) or inhibition
of chemoattractant-stimulated leukocyte migration into skin
early infiltration of glomeruli by T-lymphocytes and monocytes/
macrophages, and crescent formation and glomeruloscierosis.
Treatment of rats with anti-CD 1 la and ICAM-I prior to induc-
tion of disease and thrice weekly thereafter caused virtually
complete inhibition of crescent formation and abbrogation of
proteinuria in both studies. Furthermore, progression of disease
was retarded significantly when treatment was instituted after
disease was established [85], an important consideration if such
agents are to be useful therapeutic tools in humans.
The potential of ICAM- 1 as a target for intervention in
inflammatory renal diseases has been highlighted further in
studies of tubulointerstitial nephritis and allograft rejection.
Harning et al assessed the influence of anti-ICAM-1 mAb on
acute autoimmune tubulointerstitial nephritis in the kdkd vari-
ant of the CBA/Ca mice [86]. These animals have normal
kidneys at birth, but develop progressive and ultimately lethal
tubulointerstitial nephritis beginning after approximately four
weeks. The disease process is associated with up-regulation of
ICAM-1 expression in the renal interstitium, on infiltrating
leukocytes, and on the basolateral surface of renal tubule
epithelium. The adminstration of anti-ICAM-1 mAb to mice
with established disease caused a marked reduction in leuko-
cyte infiltration, tubular injury, and proteinuria in this model.
Interestingly, however, the use of anti-ICAM-l mAb was not
associated with increased survival.
Cosimi et al demonstrated a striking delay of renal allograft
rejection and increase in the survival of Cynomolgus monkeys
when anti-ICAM- 1 mAb was used as the sole immunosuppres-
sive agent after transplantation (recipient survival 24.4 2.4 vs.
9.2 0.6 days) [87]. In this model, increased expression of
ICAM-l was observed on arterial and peritubular, but not
glomerular endothelium, and on tubular epithelium and infiltrat-
ing leukocytes, as observed by other investigators (vide supra).
Anti-ICAM-! mAb caused some reduction in the intensity of
the T lymphocyte (CD2, CD4, and CD8) and monocyte infil-
trates in the renal interstitium and arterial endothelium, respec-
tively, suggesting that protection was mediated, at least in part,
by inhibition of leukocyte recruitment. However, anti-ICAM-l
mAb also reversed established rejection in allograft recipients
maintained on subtherapeutic doses of cyclosporin without
affecting the intensity of the leukocyte infiltrate, again suggest-
ing that mAb against adhesion molecules may have potent
Brady: Leukocyte adhesion molecules 1297
anti-inflammatory actions without altering leukocyte trafficking.
The preliminary results of a phase 1 clinical trial suggest that
anti-ICAM- 1 mAb may also prevent rejection in high risk
human allograft recipients [88].
Neutrophils contribute to tissue injury during ischemia-reper-
fusion of the pulmonary, coronary, cerebral, and splanchnic
circulations [5]. Anti-CD18 mAb confer protection against
ischemic-reperfusion injury of these organs in many experimen-
tal models [5]. The importance of neutrophils in renal ischemic-
reperfusion is less clear [89, 90] and anti-CD18 mAb did not
confer functional or morphologic protection in two rabbit
models studied to date (Table 4) [91; Neuringer J, Brady HR,
unpublished observations]. Whether this lack of efficacy re-
flects a lesser role for neutrophils in ischemia-reperfusion injury
in the kidney than in other organs, or involvement of other
adhesion molecules is unclear. These issues clearly warrant
further investigation given the prevalence of renal ischemic-
reperfusion injury in clinical practice.
There are several potential explanations for the varying
efficacy of adhesion-blocking mAb in renal diseases. Nephro-
toxic sera may differ in composition, antigen specificity and the
mechanism(s) by which they induce injury. Thus, different
adhesion molecules are likely to dominate depending on the
sera, species, and time of study. Antibodies vary dramatically
in their ability to block adhesion depending on the epitopes with
which they react and the characteristics of the antibody prep-
aration [such as intact vs. F(ab')2]. Furthermore, mAb against
CD1 l/CDI8, ICAM-1 and other adhesion molecules attenuate a
variety of other important neutrophil, lymphocyte and mono-
cyte functions such as antigen presentation, in addition to
inhibiting trafficking, as discussed above. Some mAb (particu-
lary intact mAb) provoke destruction of leukocytes in vivo. This
variable may be difficult to quantify. Children with LAD types
1 and 2 have systemic neutrophilia due to failure of margination
of granulocytes; thus, even "normal" neutrophil counts in
mAb-treated animals may not neccessarily exclude lysis of
some leukocytes subsets. Given these inherent variables and
the likely overlap of adhesion molecule function, it may difficult
to determine the relative contributions of different molecules to
renal diseases until results are accumulated using a variety of
approaches (such as different mAb, soluble forms of adhesion
molecules, anti-sense constructs, gene "knock-out" technol-
ogy, drugs, etc.).
Role of leukocyte adhesion molecules in other disease processes
Leukocyte adhesion molecules may also play a critical role in
the pathophysiology of a variety of seemingly unrelated renal
disorders which include hemodialysis membrane incompatibil-
ity reactions, atherogenesis, tumor metastasis, and the patho-
genesis of infections. Exposure of circulating blood to new
cellulosic hemodialysis membranes frequently results in rapid
activation of granulocytes, degranulation, generation of reac-
tive oxygen species, and granulocytopenia primarily due to
sequestration of granulocytes in the pulmonary vasculature
("First-use syndrome"). This granulocytopenia is usually tran-
sient and followed by rebound granulocytosis. Granulocytes
isolated from patients exposed to cellulosic membranes display
dramatic upregulation of CD1 lb/CD 18 and down-regulation of
L-selectin [94—97], suggesting that these molecules participate
in granulocyte trafficking and activation in this setting. In
keeping with this hypothesis, granulocytes from normal sub-
jects undergo dramatic degranulation when exposed to cellulo-
sic membranes in vitro, while degranulation is markedly atten-
uated with granulocytes from individuals with LAD type 1
disease [97].
Infiltration of blood vessel walls by monocytes in the area of
fatty streaks is one of the earliest pathologic events in athero-
genesis [98]. The mechanism by which monocytes are recruited
in this setting is unclear. VCAM- 1 expression is up-regulated at
an early stage on endothelium overlying plaques experimental
atherosclerosis, suggesting that VCAM-1 may promote mono-
cyte infiltration in this setting [99]. Infectious organisms may
usurp the function of adhesion molecules to infect host tissues.
For example, rhinovirus and plasmodium falciparum-infected
erythrocytes bind ICAM- 1 at sites distinct from its binding site
for CDI1a/CD18 [100, 101] and may use these interactions to
infect airway epithelium and the cerebral circulation, respec-
tively. These observations raise the exciting possibility that it
may be possible to develop antimicrobials which prevent infec-
tion by blocking the interactions between infectious organisms
and adhesion molecules such as ICAM- I without compromising
immune function. Many tumors (such as colon cancer) carry a
better prognosis if they are associated with a lymphocyte
infiltrate. Colon cancer cells display increased expression of
ICAM-1 compared to normal colonic epithelium and ICAM-1
expression appears to correlate with the degree of lymphocytic
inifitration [102]. These data suggest that ICAM-1 may play an
important role in immunosurveillance in this disease. The
expression of adhesion molecules may be a double-edged
sword; however, in cancer biology as VCAM- 1, P-selectin and
E-selectin support adhesion of some cancer cells in vitro (such
as melanoma), suggesting a mechanism whereby circulating
tumor cells may exit the circulation and seed metastases. Taken
together, these observations suggest that the further elucidation
of the molecular basis for leukocyte adhesion may not only shed
light on basic mechanisms of inflammation, but also enhance
our understanding of a variety of other biological processes and
suggest novel strategies for therapeutic intervention for many
common diseases.
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Note added in proof
Berg et al have provided recent evidence that MadCAM-l, a mucin,
is a facultative ligand for L-selectin in mesenteric lymph nodes (Nature
366:695—697, 1994). Interestingly, MadCAM-1 contains both mucin and
Ig-like residues, being a ligand for both L-selectin and cr4 /37 integrins.
This unique adaptation to support rolling and immobilization may
subserve physiologic lymphocyte homing to mesenteric lymphoid tis-
sue. The relative contributions of other mucins (CD34 and G1yCAM-1
for L-selectin; PSGL-1 for P-selectin) to selectin-mediated adhesion
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have yet to be defined (Shimizu Y and Shaw S, Nature 366:630—631,
1994). Kelly et al demonstrated a protective effect of anti-ICAM- I mAb
in renal ischemia-reperfusion, suggesting that blockade of integrin-Ig-
like interactions is beneficial in some species (Proc Nat! Acad Sci USA
91:812—816, 1994). Hill et al provided important evidence that ICAM-1
may direct migration and localization of interstitial leukocytes in
experimental glomerulonephntis (Kidney mt 45:1—12, 1994).
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